Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions
- 14 February 1998
- Vol. 316 (7131) , 589-592
- https://doi.org/10.1136/bmj.316.7131.589
Abstract
Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis. Design: Comparison of a prospective series of cases of cerebral sinus thrombosis with population data. Setting: Neurological teaching hospitals from different regions in the Netherlands (cases) and a representative sample of the non-institutionalised Dutch population (controls). Subjects: 40 women aged 18-54 years with cerebral sinus thrombosis (cases) and 2248 women aged 18-49 years (controls). Main outcome measure: Current use of oral contraceptives at the time of the thrombosis (cases) or at the time of the questionnaire (controls). Prevalences of a hereditary prothrombotic condition in patients and in the population with odds ratios. Results: 34 of 40 (85%) women with cerebral sinus thrombosis used oral contraceptives, versus 1007 of 2248 (45%) of the control women; the age adjusted odds ratio was 13 (95% confidence interval 5 to 37). Seven of 36 patients (19%) had a prothrombotic deficiency, versus 7% expected in the population; this corresponds to a threefold to fourfold increase in risk. In women who used oral contraceptives and also carried a prothrombotic defect, the odds ratio for cerebral sinus thrombosis was about 30 relative to women who had neither risk factor. Conclusion: The use of oral contraceptives and being a carrier of a hereditary prothrombotic condition increase the risk of and interact in a multiplicative way in the development of cerebral sinus thrombosis. The use of oral contraceptives is associated with an increased risk of cerebral venous sinus thrombosis This risk of cerebral venous sinus thrombosis in women who use oral contraceptives is larger if there is an additional hereditary prothombotic factor (protein C, S, or antithrombin deficiency, factor V Leiden mutation) The association between oral contraceptives, thrombophilia, and deep vein thrombosis is also valid for cerebral sinus thrombosis Women do not need to stop using oral contraceptives as the absolute risk of cerebral sinus thrombosis is very smallKeywords
This publication has 22 references indexed in Scilit:
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997
- Coagulation Studies, Factor V Leiden, and Anticardiolipin Antibodies in 40 Cases of Cerebral Venous ThrombosisStroke, 1996
- Factor V Leiden Mutation in Cerebral Venous ThrombosisStroke, 1996
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor VThe Lancet, 1994
- Prävalenz des hereditären Mangels an Antithrombin III, Protein C und Protein SDeutsche Medizinische Wochenschrift (1946), 1993
- Two ELISA's for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiencyClinica Chimica Acta; International Journal of Clinical Chemistry, 1990
- Cerebral venous thrombosis--a review of 38 cases.Stroke, 1985
- A new method for the estimation of protein C by ELISAThrombosis Research, 1984